EDIT earnings call for the period ending March 31, 2021.
News & Analysis: Editas Medicine
It wasn't the biotech's financial performance.
Investors are running for the hills following this analyst take on the biotech's prospects.
A strong overall stock market performance is lifting the biotech stock.
Short-term issues shouldn't affect long-term investors.
The stock was pulled down by the undertow of the broader market sell-off.
EDIT earnings call for the period ending .
After a huge run-up in valuation, investors are a little spooked.
Turnover at the top of a company can be troubling. But it can sometimes be a good thing.
In a field that's becoming more crowded, what will set Editas apart?